Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TS-1 vs TS-1+PSK Adjuvant Therapy for Gastric Cancer
NCT00687843Phase 3Unknown
- Sponsor
- Tokyo Metropolitan Oncology Group
- Start
- Jun 2008
- Primary completion
- Mar 2016
- Modality
- Recombinant Proteins and Enzymes, Microbiome-Derived Products
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of polysaccharide k in gastric cancer (GC) (2 arms), sponsored by Tokyo Metropolitan Oncology Group. Primary endpoint: Relapse-free survival at 5 years. Status: unknown.
02
Drugs
polysaccharide k
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT00687843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00687843.